Aarti Drugs Limited has informed the Exchange regarding Board meeting held on July 18, 2025.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs' Board, at its July 18, 2025 meeting, approved the Audited Standalone and Consolidated Financial Results for Q1 FY26 (quarter ended June 30, 2025). Notably, these are full audited results rather than the usual limited review for a quarter, which is relatively uncommon. The statutory auditor Gokhale & Sathe issued an unqualified (clean) opinion on both sets of results with no qualifications, emphasis of matter, or going concern flags. Separately, the Board appointed M/s. Mehta & Mehta, Practicing Company Secretaries, as Secretarial Auditors for a five-year term from FY2025-26 to FY2029-30, subject to shareholder approval at the next AGM. The document is from a single-business pharmaceutical company whose consolidated results include subsidiaries Pinnacle Life Science, Aarti Specialty Chemicals, and a foreign subsidiary (Pharma Go SpA via Pinnacle Chile SpA).
Neutral to mildly positive for shareholders — a clean audit opinion on quarterly results signals financial reporting discipline, while the five-year secretarial auditor appointment is routine governance. The Q1 numbers themselves are too garbled in the filing to extract reliable revenue or profit growth comparisons.